Rush Street Interactive, Inc. (RSI) closed the last trading session at $18.66, gaining 5.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.33 indicates a 30.4% upside potential.The average comprises nine short-term price targets ranging from a low of $20.00 to a high of $30.00, with a standard deviation of $2.69. While the lowest estimate indicates an increase of 7.2% from the ...

Copa Holdings (CPA) closed the last trading session at $139.34, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $180.2 indicates a 29.3% upside potential.The mean estimate comprises 10 short-term price targets with a standard deviation of $18.72. While the lowest estimate of $150.00 indicates a 7.7% increase from the current price level, the most optimistic analyst exp ...

Shares of EuroDry (EDRY) have gained 27.6% over the past four weeks to close the last trading session at $16.9, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.83 indicates a potential upside of 35.1%.The mean estimate comprises three short-term price targets with a standard deviation of $2.57. While the lowest estimate of $20.00 indicates an 18.3% increase from the current ...

Shares of Zebra Technologies (ZBRA) have gained 3.9% over the past four weeks to close the last trading session at $252.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $348.5 indicates a potential upside of 38%.The average comprises 14 short-term price targets ranging from a low of $294.00 to a high of $421.00, with a standard deviation of $33.34. While the lowest estimate i ...

Group 1 - Replimune Group, Inc. (REPL) shares have increased by 0.7% over the past four weeks, closing at $7.76, with a mean price target of $12.86 indicating a potential upside of 65.7% [1] - The average of seven short-term price targets ranges from a low of $10.00 to a high of $19.00, with a standard deviation of $3.02, suggesting a potential increase of 28.9% to 144.9% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 3.5% over the past month, indicating positive sentiment about the company's earnings prospects [11][12] Group 2 - REPL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] - While price targets are often viewed as unreliable indicators, the direction implied by these targets suggests a positive outlook for REPL [14]

Core Viewpoint - EZcorp (EZPW) has shown a significant price increase of 15.9% over the past four weeks, with a mean price target of $31.5 indicating a potential upside of 27.3% from the current price of $24.74 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $4.76, where the lowest estimate is $25.00 (1.1% increase) and the highest is $36.00 (45.5% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Agreement - Analysts have shown strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 24.1% over the past month, indicating positive sentiment as there have been no negative revisions [12] - EZPW holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, and reliance solely on them may lead to poor investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Terns Pharmaceuticals, Inc. (TERN) shows potential for significant upside, with a mean price target of $58.13 indicating a 50.9% increase from its current price of $38.52 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets, with a standard deviation of $5.19, indicating variability among analysts [2] - The lowest estimate is $54.00, suggesting a 40.2% increase, while the highest estimate is $70.00, indicating an 81.7% potential surge [2] - Analysts' price targets should be approached with caution, as they may not always accurately reflect future stock movements [3][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TERN's earnings prospects, with a consensus indicating better-than-previously estimated earnings [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 5.5% rise in the Zacks Consensus Estimate for the current year [12] - TERN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Implications of Price Target Clustering - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction [9] - While price targets can provide a starting point for further research, they should not be the sole basis for investment decisions [10][14]

Core Viewpoint - Immunovant, Inc. (IMVT) shares have shown a modest gain of 0.4% over the past four weeks, closing at $26, with analysts suggesting a potential upside of 55% based on a mean price target of $40.31 [1] Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets with a standard deviation of $13.5, indicating variability among analysts; the lowest estimate is $16.00 (38.5% decline), while the highest is $57.00 (119.2% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism regarding IMVT's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.9%, with one estimate moving higher and no negative revisions [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Vera Therapeutics, Inc. (VERA) has seen a 1.7% increase in share price over the past four weeks, closing at $49.1, with analysts suggesting a potential upside of 53.1% based on a mean price target of $75.15 [1] Price Targets - The average of 13 short-term price targets ranges from a low of $33.00 to a high of $100.00, with a standard deviation of $19.54, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 32.8% from the current price, while the highest indicates a potential upside of 103.7% [2] Analyst Sentiment - Analysts have shown increasing optimism regarding VERA's earnings prospects, with a consensus indicating better earnings than previously estimated [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.6%, with one estimate moving higher and no negative revisions [12] Zacks Rank - VERA currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of VERA's potential gains, the implied direction of price movement appears to be a useful guide [14]

Core Viewpoint - West Pharmaceutical Services (WST) shares have shown a modest gain of 0.4% recently, closing at $272.91, with analysts suggesting a potential upside of 26.4% based on a mean price target of $345 [1][4]. Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets, with a standard deviation of $28.55, indicating variability among analysts [2]. - The lowest estimate is $285.00, suggesting a 4.4% increase, while the highest estimate is $390.00, indicating a potential surge of 42.9% [2]. - A low standard deviation signifies a strong consensus among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Optimism - Analysts are increasingly optimistic about WST's earnings, as indicated by upward revisions in earnings estimates, which historically correlate with stock price movements [11]. - Over the past 30 days, one estimate has increased, leading to a 0.3% rise in the Zacks Consensus Estimate for the current year [12]. - WST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of the stock's exact gains, it does provide a useful indication of the expected price movement direction [14].